Avalyn Pharma Inc.

Nasdaq: AVLN

Day 163 public/EMERGING/IPO Apr 30, 2026/Pharmaceutical Preparations

$25.76

▲ 0.04 (+0.16%)

LIVE

updated 15h ago

Intelligence Core

MONITORING

No new filings in 72 h · watching for the next event

Current missionDurability · Day 91–180

Determine whether the company is establishing durable public-market positioning.

Focus

Sustained fundamentalsOwnershipValuationRecurring catalysts

NEUTRALFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence55%

CURRENT THESIS INTERPRETED

Avalyn Pharma Inc. is an emerging clinical-stage pharmaceutical company public for 163 days with high institutional backing shown by 7 Schedule 13D/13G filings and active insider activity, balanced against fundamental net losses and typical clinical-stage risk.

Momentum

Price · since IPOLIVE

Yahoo · 113 pts

H $39.25L $25.43Last $25.76

Current ThesisINTERPRETEDLIVE

Why

+High institutional interest with 7 Schedule 13D/13G disclosures on file
+Active insider and reporting engagement with 22 insider forms and multiple 8-K filings
+Positive equity combined with cash on the balance sheet despite ongoing net losses

Risks

−Clinical-stage sector exposure and fundamental net loss profile
−Deterministic risk score at 58 reflecting typical early-stage biotechnology uncertainties

Catalysts

→Upcoming regulatory or clinical updates derived from ongoing SEC-reported operational disclosures
→Potential shifts in institutional ownership structures via future Schedule 13 filings

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://avalynpharma.com

VIEW-ONLY

Visit

Capturing avalynpharma.com…

Screenshot of Avalyn Pharma Inc.'s official website

SNAPSHOT · live view blocked by site (X-Frame-Options: SAMEORIGIN)

Resolving official website…

Research EnvironmentLIVE

Research environment · $AVLNSEC · market · news

22 evidence items|newest evidence 8d ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 77/100 recomputed from 5 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore MONITORING · No new filings in 72 h · watching for the next event. Mission: Durability.via Intelligence Core

15h agoOBSERVATIONVERIFIEDLast price $25.76 · +0.16% on the day.via Finnhub quoteVERIFIED

8d agoEVIDENCEThis Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridayvia Benzinga · tier 3, cross-check 8d agoEVIDENCERaymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60via Benzinga · tier 3, cross-check 17d agoEVIDENCEAvalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Priceyvia Yahoo · tier 3, cross-check Sep 17, 2026EVIDENCEVERIFIEDForm 3 filed · 3.via SEC EDGARVERIFIED Sep 17, 2026EVIDENCEVERIFIEDForm 4 filed · 4.via SEC EDGARVERIFIED Sep 16, 2026EVIDENCEVERIFIEDForm 8-K filed · 8-K.via SEC EDGARVERIFIED Aug 14, 2026EVIDENCEVERIFIEDForm SCHEDULE 13G filed.via SEC EDGARVERIFIED Aug 12, 2026EVIDENCEVERIFIEDForm 10-Q filed · 10-Q.via SEC EDGARVERIFIED

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-09-17	4	4	SEC ↗
2026-09-17	3	3	SEC ↗
2026-09-16	8-K	8-K	SEC ↗
2026-08-14	SCHEDULE 13G	Avalyn Pharma Inc.	SEC ↗
2026-08-12	10-Q	10-Q	SEC ↗

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics